![Mark Payton](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Payton
Amministratore Delegato presso Caldan Therapeutics Ltd.
Posizioni attive di Mark Payton
Società | Posizione | Inizio | Fine |
---|---|---|---|
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | Amministratore Delegato | 08/03/2017 | - |
Presidente | - | - |
Storia della carriera di Mark Payton
Precedenti posizioni note di Mark Payton
Società | Posizione | Inizio | Fine |
---|---|---|---|
Celentyx Ltd.
![]() Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Direttore/Membro del Consiglio | - | - |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
GSK PLC | Corporate Officer/Principal | - | - |
Oxagen Ltd.
![]() Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 09/08/2011 | - |
Amministratore Delegato | 01/07/2002 | - | |
Direttore Tecnico/Scientifico/R&S | 01/07/2002 | - |
Formazione di Mark Payton
The University of Sheffield | Undergraduate Degree |
University of Leicester | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 7 |
Stati Uniti | 2 |
Posizioni
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Corporate Officer/Principal | 2 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
GSK PLC | Health Technology |
Aziende private | 4 |
---|---|
Oxagen Ltd.
![]() Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Health Technology |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Celentyx Ltd.
![]() Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Health Technology |
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | Commercial Services |
- Borsa valori
- Insiders
- Mark Payton
- Esperienza